In a big relief for parents, the Subject Expert Committee on Covid-19 has granted emergency use approval to Bharat Biotech's Covaxin for children in the 2-18 years age group.
India plans to test a combination of its own Covid-19 vaccine, Covaxin, and a prospective intranasal vaccine developed by US researchers, in the hopes of boosting the two vaccines' protective effectiveness against the virus.
According to the NIH, the findings show that the vaccine generates antibodies that successfully neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) forms of SARS-CoV-2, which were initially discovered in the UK and India, respectively.
The Bhubaneswar Municipal Corporation (BMC) has launched the drive-in vaccination facility for the 18-44 age group and 45+ age group from June 7th to 12th.
The advisory committee “National Technical Advisory Group on Immunisation” (NTAGI), recommended that those people who have recovered from Covid-19 should take vaccine after 6 months.
Hyderabad-based Bharat Biotech has been granted permission to conduct the phase 2 and phase 3 clinical trials of its COVID-19 vaccine ‘Covaxin’ on children between the 2 to age 18.
The required statutory clearances & permissions have also been granted for this. The target has been set to start the production of Covid Vaccine by June 2022.